Catalent (CTLT) Competitors $59.00 +0.12 (+0.20%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CTLT vs. BNTX, TEVA, BGNE, VTRS, SMMT, MRNA, GMAB, RDY, PCVX, and SRPTShould you be buying Catalent stock or one of its competitors? The main competitors of Catalent include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Catalent vs. BioNTech Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Genmab A/S Dr. Reddy's Laboratories Vaxcyte Sarepta Therapeutics Catalent (NYSE:CTLT) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is CTLT or BNTX more profitable? Catalent has a net margin of -9.28% compared to BioNTech's net margin of -15.16%. Catalent's return on equity of -0.66% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets Catalent-9.28% -0.66% -0.24% BioNTech -15.16%-2.35%-2.05% Do analysts prefer CTLT or BNTX? Catalent currently has a consensus price target of $63.40, indicating a potential upside of 7.46%. BioNTech has a consensus price target of $138.79, indicating a potential upside of 35.88%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Catalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Catalent 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.81 Does the media prefer CTLT or BNTX? In the previous week, BioNTech had 17 more articles in the media than Catalent. MarketBeat recorded 30 mentions for BioNTech and 13 mentions for Catalent. Catalent's average media sentiment score of 0.67 beat BioNTech's score of 0.31 indicating that Catalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalent 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in CTLT or BNTX? 15.5% of BioNTech shares are held by institutional investors. 0.3% of Catalent shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in CTLT or BNTX? Catalent received 504 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.87% of users gave Catalent an outperform vote while only 45.48% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformCatalentOutperform Votes64057.87% Underperform Votes46642.13% BioNTechOutperform Votes13645.48% Underperform Votes16354.52% Which has more volatility & risk, CTLT or BNTX? Catalent has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Which has higher valuation and earnings, CTLT or BNTX? BioNTech has lower revenue, but higher earnings than Catalent. BioNTech is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCatalent$4.38B2.44-$1.04B-$2.26-26.11BioNTech$3.04B8.05$1.01B-$2.10-48.64 SummaryBioNTech beats Catalent on 10 of the 19 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Catalent News Delivered to You Automatically Sign up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTLT vs. The Competition Export to ExcelMetricCatalentPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$10.71B$6.41B$5.01B$19.85BDividend YieldN/A8.11%5.16%3.52%P/E Ratio-26.1110.57134.3742.73Price / Sales2.44243.641,158.6819.27Price / Cash22.5322.1633.5317.86Price / Book2.965.474.675.52Net Income-$1.04B$153.61M$119.07M$986.45M7 Day Performance0.08%-2.00%-1.83%0.45%1 Month Performance-1.99%-7.47%-3.62%1.05%1 Year Performance48.09%31.80%31.63%24.67% Catalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900BNTXBioNTech3.4698 of 5 stars$102.14-4.0%$138.79+35.9%+3.3%$24.49B$3.04B-48.646,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.58B$15.43B0.0038,000SMMTSummit Therapeutics1.8653 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3073 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.57B$2.39B19.852,204RDYDr. Reddy's Laboratories1.3247 of 5 stars$14.30-0.3%$17.00+18.9%+5.9%$11.94B$299.87B22.7027,048PCVXVaxcyte3.2906 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160SRPTSarepta Therapeutics4.9373 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.64B88.691,314Analyst DowngradeGap Up Related Companies and Tools Related Companies BioNTech Alternatives Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Viatris Alternatives Summit Therapeutics Alternatives Moderna Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Vaxcyte Alternatives Sarepta Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CTLT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
